The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
D000208:Acute Disease; D058916:Adenosine A1 Receptor Antagonists; D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016001:Confidence Intervals; D018450:Disease Progression; D004231:Diuresis / Q000187:drug effects; D004417:Dyspnea / Q000517:prevention & control; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D051437:Renal Insufficiency / Q000150:complications* / Q000503:physiopathology / Q000517:prevention & control*; D012306:Risk; D012307:Risk Factors; D014970:Xanthines / Q000008:administration & dosage*
D058916:Adenosine A1 Receptor Antagonists; D002317:Cardiovascular Agents; D014970:Xanthines; C073525:rolofylline